Skip to main content

Advertisement

Table 2 Input values in the base case analysis

From: Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

  FCM Placebo Source
Proportion of patients according to NYHA class at baseline
  NYHA class II 0.17 0.19 Anker 2009 [16]
  NYHA class III 0.83 0.81 Anker 2009 [16]
Proportion of patients according to NYHA class at 24 weeks
  NYHA class I 0.06 0.01 Anker 2009 [16]
  NYHA class II 0.41 0.29 Anker 2009 [16]
  NYHA class III 0.5 0.65 Anker 2009 [16]
  NYHA class IV 0.01 0.03 Anker 2009 [16]
  Death 0.02 0.03 Anker 2009 [16]
Total medication cost (IDA treatment cost) US $645 0  
  FCM price (500 mg vial) US $160 0 Suggested price
  Dose 1,000 mg 0 KNF
  No. of infusions 2 0 Gutzwiller 2012 [19]
  Normal saline price (200 mL) US $1.8 0 HIRA weighted price
  Infusion fee US $1.1 0 NHI fee schedule
Adjusted CHF medical cost by NYHA class excluding cost of IV iron treatment (6 months)
  NYHA class I US $510 US $510 See Table 1
  NYHA class II US $928 US $928 See Table 1
  NYHA class III US $1,623 US $1,623 See Table 1
  NYHA class IV US $3,142 US $3,142 See Table 1
Utility weight according to NYHA class (1 year)
  NYHA class I 0.93 0.93 Fox 2007 [21]
  NYHA class II 0.78 0.78 Fox 2007 [21]
  NYHA class III 0.61 0.61 Fox 2007 [21]
  NYHA class IV 0.44 0.44 Fox 2007 [21]
Utility difference from the FAIR-HF study 0.037 (scenario 2) Gutzwiller 2012 [19]  
  1. FCM, ferric carboxymaltose; IDA, iron-deficiency anemia; KNF, Korean National Formulary; NYHA, New York Heart Association; NHI, national health insurance; No, Number; IV, intravenous.